The Anti-CCP ELISA is a sensitive and accurate test for the detection of autoantibodies to the CCP protein. In persons who do not have any symptoms of the disease, a positive Anti-CCP antibody titre is predictive of the onset of RA in the future. This test is a rapid and reliable diagnostic tool, favouring early treatment implementation. This study was conducted with anti-CCP antibodies diluted in the serum of 112 patients with RA and 136 healthy controls.
The Anti-CCP ELISA is based on peptide epitopes on the surface of microwells. The protein is highly purified. A pre-coated microwell contains the peptide. The patient serum or plasma contains specific antibodies to the peptide, which binds to the immobilized antigen. A wash step is necessary to remove unbound serum or plasma components.
If a patient is experiencing disease activity, the physician may order the anti-CCP test. This test is 97% specific for RA and remains positive throughout the disease. However, 20% of RA patients are seronegative. Anti-CCP and RF are not routinely repeated once a patient has been diagnosed with RA. However, if a physician suspects a patient has RA, she may continue to order the tests to monitor the disease's activity.
The positive predictive value of the anti-CCP ELISA is a critical factor in determining the occurrence of erosive arthritis. The test has a low PPV for patients with pSS, polymyositis, and systemic sclerosis, but a high PPV for people with dermatomyositis. This test is also useful for monitoring radiological damage.
The Anti-CCP ELISA test is a highly sensitive and specific autoantibody. Anti-CCP antibody is often found early in the disease, making it a reliable way to diagnose rheumatoid arthritis. The test can be used to rule out other rheumatoid arthritis. Although the test is not 100% accurate, it has a high predictive value for predicting the progression of the disease. Residues on the plate also affect the accuracy of testing. It is expected to clean the ELISA plate after detecting by using plate washer.
Anti-CCP ELISA testing is a cheap, reliable way to monitor the effectiveness of pharmacological therapy. Its sensitivity and specificity are similar to those of the RF. RF results have a positive predictive value of about 100%. Anti-CCP antibody levels do not necessarily correlate with the evolution stage of an illness, and levels are often detectable years before symptoms. This makes the test a useful tool to monitor a patient's progress.
The anti-CCP antibody is often detected in patients with non-RA CTD, and this positive rate is higher than the general population. In addition to RA, anti-CCP antibody is also detected in tuberculosis and autoimmune hepatitis. The anti-CCP antibody recognizes the citrulline residue in CCP. It then reacts with the arginine form of CCP.
The authors used a database of CTD patients that did not develop RA as their primary diagnosis. The results indicated that only 2 out of 33 of these patients met the criteria for RA based on the 1987 revised American College of Rheumatology. All 33 anti-CCP-positive non-RA CTD patients were followed for at least a year and assessed for the development of RA. X-rays were also used to assess bone erosions in the hands and feet.